and from another well respected source that has the 'talent' to perceive and share those perceptions in a credible fashion!
"thanks spin - and to jaybe for posting the report. So the pts that were unresponsive to IMA (n=4) or DAS (n=1), at a median follow up for 22 mo, resulted in 3 pts with MR4.5 and 1 pt with MR4. Even the DAS-resistant pt had a partial cytogenetic response. Equally important, pts quickly had doses reduced to 15 mg/d. This augurs well for the early (3 mo assessment on IMA) switch study. 15-20% of newly diagnosed CP CML pts are considered "poorly responsive" to IMA and would likely benefit from the early switch. Extrapolating from this small study, the vast majority should respond and receive PON for years and at least half should achieve MR4.5, the ultimate target for reducing the leukemic cell mass, associated with long-term non progression.
this report, from the World's leading CML clinical research group, represents an advance in management of CP CML. Good for pts and ARIA"
galt
